What's the most fascinating quirk of science? Some might say it's the boundless nature of the universe, or the extreme conditions under which life is able to thrive. But perhaps the most amazing of them all is the small, complex machinery that runs largely unnoticed within our bodies. Trillions of cells work tirelessly every day to produce what we call “life.” That is, of course, until something goes wrong.

Even a small mutation in our genetic code can cause a deadly cancer to arise. Pancreatic ductal adenocarcinoma (PDAC) often stands out among these cancers. In 2026, it was predicted to account for only 3.2% of new cancer cases but 8.4% of all cancer deaths within the U.S.. Modern cancer therapies like mRNA vaccines and immunotherapy are being tested to combat PDAC, but so far, very few tested therapies have stuck around. One drug, pembrolizumab , was recently FDA approved but only impacts about 1% of PDAC patients. Even with modern medicine’s standard of care, PDAC has only inched up to a 13.7% five- year survival rate.

The reason PDAC is so difficult to treat comes down to a single protein: KRAS . KRAS is one of three RAS protein subtypes, and it’s implicated in about 25-30% of all human cancers. In healthy cells, RAS functions as a molecular switch. When it’s turned “on,” cells grow and divide. When it’s turned “off,” they stop. But mutations can lock this switch permanently into the “on” position, causing uncontrolled growth. With more than 90% of pancreatic cancers carrying these KRAS mutations, researchers have tried for the last four decades to build drugs that could flip the switch back off. They couldn’t. The protein’s surface is flat and smooth, lacking the grooves and pockets that drugs need to grab onto. Scientists deemed KRAS “undruggable.”

Then came daraxonrasib. Rather than trying to wedge into a nonexistent pocket on the protein, daraxonrasib takes a different approach. It’s what’s known as a RAS (ON) inhibitor due to its ability to target RAS in its active, GTP-bound state as opposed to the inactive state that previous drugs attempted to reach. Taken orally once a day, daraxonrasib binds to an existing protein in the body called cyclophilin A . Together, they form a complex that latches onto the active KRAS protein and blocks it from sending growth signals to cancer cells. In short, the drug recruits the body’s own molecular machinery to shut down a target that couldn’t be reached by conventional means.

Developed by Revolution Medicines, daraxonrasib was tested in a Phase 3 study of 500 patients with previously treated metastatic PDAC. The results were striking. Patients taking daraxonrasib had a median overall survival of 13.2 months, compared to 6.7 months on standard chemotherapy with fewer severe side effects. When these results were presented at the 2026 American Society of Clinical Oncology Annual Meeting, the audience responded with a 42-second standing ovation, with some in the crowd moved to tears. On August 26, 2026, the FDA approved daraxonrasib under the brand name Rasonque, 6.5 months ahead of its review deadline.

For those with PDAC, the drug represents the first real targeted treatment option for a disease that has resisted nearly everything thrown its way. The implications extend beyond just pancreatic cancer as well; daraxonrasib is currently being studied as a first-line treatment for PDAC and as a second-line option in non-small cell lung cancer. Because it targets RAS broadly rather than a single mutation, it could potentially treat any cancer driven by RAS. Forty years of being “undruggable” may finally have an answer after all.